- Home
- MDXH vs IKT Comparison
MDXH vs IKT Comparison
Compare MDXH & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDXH
- IKT
- Stock Information
- Founded
- MDXH 2003
- IKT 2008
- Country
- MDXH Belgium
- IKT United States
- Employees
- MDXH N/A
- IKT N/A
- Industry
- MDXH
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- MDXH
- IKT Health Care
- Exchange
- MDXH Nasdaq
- IKT Nasdaq
- Market Cap
- MDXH 141.1M
- IKT 140.5M
- IPO Year
- MDXH 2021
- IKT 2020
- Fundamental
- Price
- MDXH $3.55
- IKT $1.80
- Analyst Decision
- MDXH Buy
- IKT Buy
- Analyst Count
- MDXH 1
- IKT 2
- Target Price
- MDXH $6.00
- IKT $8.00
- AVG Volume (30 Days)
- MDXH 172.3K
- IKT 101.1K
- Earning Date
- MDXH 08-05-2025
- IKT 08-14-2025
- Dividend Yield
- MDXH N/A
- IKT N/A
- EPS Growth
- MDXH N/A
- IKT N/A
- EPS
- MDXH N/A
- IKT N/A
- Revenue
- MDXH $98,953,000.00
- IKT N/A
- Revenue This Year
- MDXH $24.77
- IKT N/A
- Revenue Next Year
- MDXH $22.21
- IKT N/A
- P/E Ratio
- MDXH N/A
- IKT N/A
- Revenue Growth
- MDXH 22.56
- IKT N/A
- 52 Week Low
- MDXH $1.35
- IKT $1.12
- 52 Week High
- MDXH $3.81
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- MDXH 73.83
- IKT 52.36
- Support Level
- MDXH $2.86
- IKT $1.77
- Resistance Level
- MDXH $3.81
- IKT $1.87
- Average True Range (ATR)
- MDXH 0.22
- IKT 0.15
- MACD
- MDXH 0.05
- IKT 0.02
- Stochastic Oscillator
- MDXH 78.15
- IKT 72.97
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.